1 enrolling by invitation. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP Riliprubart Prefilled Pen (PFP) - Polyneuropathy, Inflammatory Demyelinating, Chronic | Phase 3 | Enrolling by invitation | Sanofi | 300 | 2025-04-01 | 2026-10-27 |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1)
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Chronic Disease (1) · Disease Attributes (1) · Immune System Diseases (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Peripheral Nervous System Diseases (1) · Polyneuropathies (1) · Polyradiculoneuropathy (1)
Sanofi (1)
Argentina (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · Poland (1)